Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Review Cost For Sanofi/Regeneron’s PCSK9 Inhibitor Remains Uncertain

Sep 16 2014

• By Derrick Gingery

Related Content

FDA Priority Review Costs Remain Stable While Voucher Fee Ticks Up

Sep 01 2014

Priority Review Vouchers For Pediatric Rare Disease: Will Popularity Force A Quick Halt?

Mar 24 2014

For Sale: Knight Therapeutics Seeks Buyers For Impavido Priority Review Voucher

Mar 20 2014

Priority Review Voucher Value Still Confounds, But Remains An Incentive For Sponsors

Sep 21 2011

How Much Is A Priority Review Worth? $67.5 Million, Sanofi/Regeneron Say

Aug 11 2014

BioMarin Tests FDASIA’s Pediatric Voucher Waters With <em>Vimizim</em> Approval

Feb 24 2014

Related Companies

BioMarin Pharmaceutical Inc.

Sanofi

Regeneron Pharmaceuticals, Inc.

Knight Therapeutics, Inc.

Additional Topics

United States Drug Approval Standards BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window